fosphenytoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiepileptics, hydantoin derivatives	1247	93390-81-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fosphenytoin cerebyx fosphenytoin sodium fosphenytoin sodium hydrate	Molecular weight: 362.28 Formula: C16H15N2O6P CLOGP: 0.81 LIPINSKI: 0 HAC: 8 HDO: 3 TPSA: 116.17 ALOGS: -3.40 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fosphenytoin
cerebyx
fosphenytoin sodium
fosphenytoin sodium hydrate

Molecular weight: 362.28
Formula: C16H15N2O6P
CLOGP: 0.81
LIPINSKI: 0
HAC: 8
HDO: 3
TPSA: 116.17
ALOGS: -3.40
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.45	g	P

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.06 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.16 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 5, 1996	FDA	PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Status epilepticus	155.63	41.52	44	1775	13362	50589943
Drug ineffective	127.79	41.52	150	1669	819183	49784122
Multiple-drug resistance	108.95	41.52	25	1794	3289	50600016
Oropharyngeal oedema	81.35	41.52	13	1806	243	50603062
Macroglossia	69.49	41.52	13	1806	625	50602680
Laryngeal stenosis	66.60	41.52	13	1806	784	50602521
Seizure	58.97	41.52	42	1777	117832	50485473
Acquired macroglossia	56.37	41.52	9	1810	167	50603138
Necrotising colitis	52.97	41.52	10	1809	505	50602800
Drug reaction with eosinophilia and systemic symptoms	52.93	41.52	24	1795	28400	50574905
Hepatic function abnormal	49.73	41.52	24	1795	32657	50570648

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Status epilepticus	114.58	35.63	36	1510	10758	29562223
Drug ineffective	75.58	35.63	93	1453	363077	29209904
Seizure	60.47	35.63	45	1501	93078	29479903
Rhabdomyolysis	54.90	35.63	36	1510	60772	29512209
Cardiac arrest	45.99	35.63	37	1509	85554	29487427

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Status epilepticus	233.65	33.77	73	3270	21590	64473799
Drug ineffective	183.02	33.77	219	3124	840028	63655361
Multiple-drug resistance	96.21	33.77	28	3315	6474	64488915
Seizure	87.70	33.77	71	3272	166821	64328568
Oropharyngeal oedema	76.62	33.77	13	3330	242	64495147
Drug reaction with eosinophilia and systemic symptoms	71.92	33.77	41	3302	54176	64441213
Hepatic function abnormal	62.93	33.77	40	3303	64273	64431116
Laryngeal stenosis	61.68	33.77	13	3330	794	64494595
Cardiac arrest	61.41	33.77	56	3287	154008	64341381
Nystagmus	59.32	33.77	21	3322	9047	64486342
Macroglossia	58.00	33.77	13	3330	1059	64494330
Bradycardia	55.14	33.77	47	3296	118172	64377217
Rhabdomyolysis	54.47	33.77	42	3301	91684	64403705
Hypotension	52.22	33.77	80	3263	380894	64114495
Acquired macroglossia	51.35	33.77	9	3334	204	64495185
Off label use	44.96	33.77	100	3243	632706	63862683
Drug ineffective for unapproved indication	42.48	33.77	24	3319	31109	64464280
Blood pressure decreased	41.65	33.77	35	3308	86164	64409225
Electrocardiogram QRS complex prolonged	40.65	33.77	16	3327	9228	64486161
Respiratory depression	37.29	33.77	20	3323	23423	64471966
Anticonvulsant drug level below therapeutic	37.27	33.77	9	3334	1015	64494374
Anticonvulsant drug level increased	34.10	33.77	10	3333	2367	64493022

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N03AB05	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Hydantoin derivatives
FDA PE	N0000008486	Decreased Central Nervous System Disorganized Electrical Activity
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026941	Sodium Channel Blockers
FDA EPC	N0000175753	Anti-epileptic Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Epilepsy	indication	84757009	DOID:1826
Status epilepticus	indication	230456007	DOID:1824
Epilepsy characterized by intractable complex partial seizures	indication	442481002
Seizures in Neurosurgery	indication
Alcoholism	contraindication	7200002
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Complete atrioventricular block	contraindication	27885002
Lymphadenopathy	contraindication	30746006
Torsades de pointes	contraindication	31722008
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Stokes-Adams syndrome	contraindication	46935006
Sinus bradycardia	contraindication	49710005
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Prolonged QT interval	contraindication	111975006
Hypoalbuminemia	contraindication	119247004
Pancytopenia	contraindication	127034005	DOID:12450
Second degree atrioventricular block	contraindication	195042002
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Granulocytopenic disorder	contraindication	417672002
Congenital long QT syndrome	contraindication	442917000
HLA-B 1502 Positive Status	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.77	acidic
pKa2	5.83	acidic
pKa3	8.0	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium channel protein type 5 subunit alpha	Ion channel	Q14524	SCN5A_HUMAN	BLOCKER				DRUGBANK	CHEMBL

External reference:

ID	Source
4024030	VUID
N0000022035	NUI
D02096	KEGG_DRUG
92134-98-0	SECONDARY_CAS_RN
4020973	VANDF
4024030	VANDF
C0244656	UMLSCUI
CHEBI:5165	CHEBI
CHEMBL1201336	ChEMBL_ID
DB01320	DRUGBANK_ID
CHEMBL919	ChEMBL_ID
C043114	MESH_SUPPLEMENTAL_RECORD_UI
56339	PUBCHEM_CID
7190	IUPHAR_LIGAND_ID
6484	INN_ID
B4SF212641	UNII
134860	RXNORM
117573	MMSL
4767	MMSL
6028	MMSL
d04041	MMSL
006181	NDDF
006182	NDDF
108397000	SNOMEDCT_US
372484000	SNOMEDCT_US
386843000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CEREBYX	HUMAN PRESCRIPTION DRUG LABEL	1	0069-5471	INJECTION, SOLUTION	50 mg	INTRAVENOUS	NDA	28 sections
CEREBYX	HUMAN PRESCRIPTION DRUG LABEL	1	0069-5474	INJECTION, SOLUTION	50 mg	INTRAVENOUS	NDA	28 sections
CEREBYX	HUMAN PRESCRIPTION DRUG LABEL	1	0069-6001	INJECTION, SOLUTION	50 mg	INTRAVENOUS	NDA	27 sections
CEREBYX	HUMAN PRESCRIPTION DRUG LABEL	1	0069-6001	INJECTION, SOLUTION	50 mg	INTRAVENOUS	NDA	27 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9782	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	26 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9788	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	26 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6136	INJECTION	50 mg	INTRAMUSCULAR	ANDA	26 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6137	INJECTION	50 mg	INTRAMUSCULAR	ANDA	26 sections
Fosphenytoin	HUMAN PRESCRIPTION DRUG LABEL	1	63323-403	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	30 sections
FOSPHENYTOIN SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	64679-729	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
FOSPHENYTOIN SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	64679-730	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	65162-998	INJECTION	50 mg	INTRAMUSCULAR	ANDA	18 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	65162-999	INJECTION	50 mg	INTRAMUSCULAR	ANDA	18 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-516	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	22 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-517	INJECTION, SOLUTION	50 mg	INTRAVENOUS	ANDA	22 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1381	INJECTION	50 mg	INTRAMUSCULAR	ANDA	26 sections
Fosphenytoin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1390	INJECTION	50 mg	INTRAMUSCULAR	ANDA	26 sections
Sesquient	HUMAN PRESCRIPTION DRUG LABEL	1	80674-102	INJECTION, SOLUTION	100 mg	INTRAVENOUS	NDA	27 sections
Sesquient	HUMAN PRESCRIPTION DRUG LABEL	1	80674-210	INJECTION, SOLUTION	500 mg	INTRAVENOUS	NDA	27 sections